Olive Leaf Extract for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Olive Leaf Extract for Health & Longevity

Created on 08/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A concentrated olive leaf preparation. Its best-supported effect is modestly lowering blood pressure in people whose pressure is already raised, with smaller and less reliable improvements in blood fats. Effects on blood sugar, inflammation, weight and knee pain are contested. Benefits concentrate in people starting with abnormal values; stomach upset is the usual complaint. (Full Review)

Protocol

Standard oral dose
500 mg once or twice daily
Standardised extract, the dose in most positive trials, delivering 50–160 mg oleuropein
Oleuropein target
100–140 mg daily
Spans most positive results. Oleuropein milligrams are the figure that matters, not extract milligrams: concentration ranges from 1% to 40%
Best time of day
Morning with breakfast
Standard in the trials that measured morning home blood pressure; twice-daily split dosing matches the few-hour metabolite half-life
Time to effect
Blood pressure
4–8 weeks
In the trials that found an effect. A judgement before eight weeks is premature
Lipids
6 weeks
Lipid changes appeared by six weeks
Insulin sensitivity
12 weeks
Improvement appeared at twelve weeks; bone-turnover markers moved only at twelve months

Benefits

Contraindications
  • Pregnant or breastfeeding women
  • Confirmed olive or olive-pollen allergy, including olive-pollen-associated food allergy
  • Moderate or severe hepatic impairment (Child-Pugh Class B or C)
  • Symptomatic hypotension (seated systolic below 100 mmHg or recurrent orthostatic symptoms)
  • Recurrent hypoglycemia on insulin or sulfonylureas (more than one episode below 3.9 mmol/L per week)
  • Adults within two weeks of elective surgery
    •
Key Interactions
  • Antihypertensive drugs (lisinopril, captopril, losartan, valsartan)
  • Calcium channel blockers and diuretics (amlodipine, diltiazem, hydrochlorothiazide)
  • Glucose-lowering drugs (insulin, glibenclamide, gliclazide, repaglinide)
  • Anticoagulants and antiplatelets (warfarin, apixaban, clopidogrel, aspirin)
  • Levothyroxine and antithyroid drugs
  • Over-the-counter medicines (ibuprofen and other NSAIDs, pseudoephedrine-containing decongestants, antacids)
  • Blood-pressure-lowering supplements (beetroot or dietary nitrate, hibiscus, garlic extract, magnesium, potassium, coenzyme Q10)
  • Blood-sugar-lowering supplements (berberine, cinnamon extract, alpha-lipoic acid, chromium)
  • Iron supplements
  • Other interventions (cold-water immersion, fasting, high-dose olive oil polyphenols)

Risk & Side Effects

  • High:
  • Medium: Gastrointestinal symptoms
    •
  • Low: Symptomatic low blood pressure with antihypertensive therapy; additive blood-sugar lowering with diabetes medication; allergic reactions in olive-sensitised people; liver effects; undeclared content and dose variability in commercial products
  • Speculative: Thyroid stimulation; reduced non-heme iron absorption

Monitoring

Marker Target Why
Home systolic / diastolic blood pressure 110–120 / 70–75 mmHg Best-evidenced outcome; defines whether there is anything to improve
Fasting glucose 4.4–5.0 mmol/L (79–90 mg/dL) Detects the additive hypoglycemia risk and the target for glycemic benefit
HbA1c 4.8–5.2% Three-month average glucose; the endpoint of the only positive diabetes trial
LDL cholesterol Below 2.0 mmol/L (77 mg/dL) One of the two lipid markers the extract moves in positive trials
Apolipoprotein B Below 0.8 g/L Counts artery-damaging particles; not moved by any olive leaf trial but the better risk marker
Triglycerides Below 1.0 mmol/L (89 mg/dL) The lipid fraction most consistently reduced across pooled analyses
High-sensitivity C-reactive protein Below 1.0 mg/L Tests the claimed anti-inflammatory effect, which trials contradict each other on
Alanine and aspartate aminotransferase Below 25 U/L (women), below 30 U/L (men) Addresses the isolated hepatic toxicity case report
Thyroid-stimulating hormone and free thyroxine TSH 1.0–2.0 mIU/L; free thyroxine in the upper half of the laboratory range Animal data show thyroid stimulation; relevant to anyone on thyroid replacement
Ferritin 50–125 µg/L Tests the theoretical polyphenol iron-binding effect in anyone with borderline iron status
24-hour ambulatory blood pressure Mean below 130/80 mmHg Used in the strongest trials; detects night-time effects home monitoring misses

Cadence: Home blood pressure daily for the first four weeks, then weekly; fasting glucose twice daily for two to four weeks for anyone on insulin or a sulfonylurea; repeat laboratory panel at 12 weeks, then every 6–12 months on continued use; liver enzymes and, on thyroid replacement, thyroid function rechecked at three months.

Qualitative Assessment

  • Dizziness or light-headedness on standing, the earliest sign of additive blood-pressure lowering
  • Frequency and severity of stomach discomfort, nausea or reflux in the first four weeks
  • Number of sick days during respiratory illness season
  • Cold sore healing time, for anyone using the topical form
  • Perceived joint comfort and walking pain, for anyone taking it on the joint indication
  • Menopausal symptom burden, including hot flush frequency and interference with daily activity
  • Perceived energy and exercise tolerance during moderate-intensity sessions
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.